1-N-cyclobutylpropane-1,2-diamine | 1247613-57-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-N-cyclobutylpropane-1,2-diamine
• CAS: 1247613-57-5
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: JKLJKSNVOAWSMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[2,8-二(三氟甲基)-4-喹啉基]环氧乙烷 、 1-N-cyclobutylpropane-1,2-diamine 以 乙醇 为溶剂， 反应 0.25h， 以21%的产率得到1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(1-(cyclobutylamino)propan-2-ylamino)ethanol
  参考文献：
  名称：

  Structure–Activity Relationships of 4-Position Diamine Quinoline Methanols as Intermittent Preventative Treatment (IPT) against Plasmodium falciparum

  摘要：

  A library of diamine quinoline methanols were designed based on the mefloquine scaffold. The systematic variation of the 4-position amino alcohol side chain led to analogues that maintained potency while reducing accumulation in the central nervous system (CNS). Although the mechanism of action remains elusive, these data indicate that the 4-position side chain is critical for activity and that potency (as measured by IC(90)) does not correlate with accumulation in the CNS. A new lead compound, (S)-1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(2-(cyclopropylamino)ethylamino)ethanol (WR621308), was identified with single dose efficacy and substantially lower permeability across MDCK cell monolayers than mefloquine. This compound could be appropriate for intermittent preventative treatment (IPTx) indications or other malaria treatments currently approved for mefloquine.

  DOI：

  10.1021/jm200647u

文献信息

• PPAR agonists and methods of use thereof
  申请人：The Salk Institute for Biological Studies

  公开号：US10035819B2

  公开（公告）日：2018-07-31

  Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds have a formula where L5 comprises at least one deuterium. Exemplary species include The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

  本文提供了有助于提高 PPARδ 活性的氚代化合物和组合物。这些化合物的化学式为 其中 L5 包含至少一个氘。示例物种包括 本文提供的化合物和组合物可用于治疗 PPARδ 相关疾病（如肌肉疾病、血管疾病、脱髓鞘疾病和代谢性疾病）。
• PPAR agonists
  申请人：Salk Institute for Biological Studies

  公开号：US10550071B2

  公开（公告）日：2020-02-04

  Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

  本文提供的是有助于提高 PPARδ 活性的化合物和组合物。本文提供的化合物和组合物可用于治疗 PPARδ 相关疾病（如肌肉疾病、血管疾病、脱髓鞘疾病和代谢性疾病）。
• PPAR AGONISTS AND METHODS OF USE THEREOF
  申请人：The Salk Institute for Biological Studies

  公开号：US20170226154A1

  公开（公告）日：2017-08-10

  Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
• PPAR AGONISTS
  申请人：Salk Institute for Biological Studies

  公开号：US20180170857A1

  公开（公告）日：2018-06-21

  Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
• NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US20220144802A1

  公开（公告）日：2022-05-12

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.